Loading…
← CockpitCompetitor Analysis › 002424.SZ Guizhou Bailing Group Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A002424.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 49
Mkt cap
$755M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$3.90M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-1.9 pp
WACC 5.0%
Hurdle
+14 pp
Req g minus delivered
Close · CNYCN¥3.88
1D-5.1%
1W-12.2%
1M-14.3%
3M-16.7%
6M-20.5%
YTD-10.8%
1Y-33.7%
ATR %2.4%
52w lowhigh37.9% off high

What Guizhou Bailing Group Pharmaceutical does

Employees: 5,715

Guizhou Bailing Group Pharmaceutical at a glance

Size Guizhou Bailing Group Pharmaceutical (002424.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $755M, the 2710th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.88 on 18 Nov 2026.

Performance Over six months the shares fell 20.5%, against -8.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.

Growth Revenue fell 25.2% over the last twelve months (peer median +3.5%); the operating margin is 2.5% (peer median 9.6%).

Valuation It trades at 2.5× enterprise value to sales against a peer median of 2.6× (9th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.9 points below its cost of capital (5.0% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 93002424.SZ 80
Six months, rebased to 100: Guizhou Bailing Group Pharmaceutical against the median of its 20 peers (local-currency closes).

Guizhou Bailing Group Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.36BCN¥3.02BCN¥3.79BCN¥4.21BCN¥3.49B
Revenue growth—-20%-10%+21%—
Gross profitCN¥973MCN¥1.37BCN¥2.14BCN¥2.25BCN¥2.04B
EBITDAn/aCN¥223MCN¥179M-CN¥293MCN¥326M
Net income-CN¥129M-CN¥104MCN¥33.6M-CN¥415MCN¥138M
Free cash flowCN¥132MCN¥635M-CN¥24.2MCN¥30.4MCN¥395M
Capital expenditureCN¥113MCN¥125MCN¥42.0MCN¥104MCN¥68.5M
Total debtCN¥1.06BCN¥1.29BCN¥1.89BCN¥1.78BCN¥1.70B

Quarterly statements and history in the cockpit →

Guizhou Bailing Group Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%+50%00290721716004793001LXRX0023903007052186BLISSGVS000411ARDX600530688799SGMTIRWDGUD002424.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Guizhou Bailing Group Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×10×20×30×00290721716004793001LXRX0023902186BLISSGVSARDX002349600530IRWDGUD002424.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guizhou Bailing Group Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%00290760047930010023903007052186BLISSGVS688566600530GUD002424.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guizhou Bailing Group Pharmaceutical is the large dot.

Guizhou Bailing Group Pharmaceutical competitors and peer comparison

How Guizhou Bailing Group Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guizhou Bailing Group Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002424.SZPeer medianRank in peer set
1-month return-14.3%-3.7%4th lowest of 19
6-month return-20.5%-8.5%8th lowest of 19
Distance from 52-week high-37.9%-32.6%6th lowest of 19
Revenue growth (TTM)-25.2%+3.5%2nd lowest of 19
Operating margin2.5%9.6%5th lowest of 19
EV / Sales2.5×2.6×9th cheapest of 18
Growth the price implies (Req g, 7 yrs)13.5%0.3%3rd most demanding of 12
Growth delivered (Del g)-0.2%+1.9%4th lowest of 12
Hurdle (Req g minus delivered)+13.7 pp-3.1 pp3rd most demanding of 12
ROIC minus cost of capital-1.9 pp+0.2 pp6th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%

Questions

Which companies are Guizhou Bailing Group Pharmaceutical's closest peers?
The cockpit's peer set: Chongqing Pharscin Pharmaceutical (002907.SZ), CARsgen Therapeutics (2171.HK), Zhuzhou Qianjin Pharmaceutical (600479.SS), Katakura Industries (3001.T), Lexicon Pharmaceuticals (LXRX), Guizhou Xinbang Pharmaceutical (002390.SZ), Hunan Jiudian Pharmaceutical (300705.SZ), Luye Pharma (2186.HK).
Is Guizhou Bailing Group Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 2.5× against a peer median of 2.6×, 9th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Guizhou Bailing Group Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -20.5% against -8.5% for the median peer; over one year -33.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.